14.57
+0.14%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anika Therapeutics
From its filings with the US Securities and Exchange Commission
Anika Therapeutics is based in Bedford, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ANIK. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $112.8m and a net loss of $10.9m. At that date it held total assets of $190.3m and shareholders' equity of $143.5m. By business, OEM Channel [Member] brought in 57.1% of revenue, followed by Commercial Channel [Member] at 42.9%. By region, UNITED STATES accounted for 62.1%, followed by Europe [Member] at 19.7% and Other Location [Member] at 18.2%.
Founded in 1992, Anika Therapeutics, Inc. (“Anika” or “Company”) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid (“HA”) technology to develop highly differentiated products. Driven by strong partnerships with physicians, Anika is dedicated to pioneering HA-based innovations that redefine orthopedic care. Our mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide.
In October 2024, we announced a strategic shift to concentrate on our OA Pain Management and Regenerative Solutions portfolios. This strategic decision involved the sale of Arthrosurface Incorporated on October 31, 2024 and the sale of Parcus Medical, LLC on March 7, 2025, both of which were acquired in early 2020 under a previous management strategy.
As we look ahead, our focused strategy, driven by HA-based products, positions us to offer truly innovative treatments in areas of unmet need and substantial, growing markets. We will place particular emphasis on the commercial execution and adoption of the newest product in our Regenerative Solutions portfolio, the Integrity Implant System (“Integrity”), a HA-based scaffold designed for rotator cuff and other tendon repairs. The Integrity system has shown strong performance, with continuing growth in surgeries and significant adoption by new customers.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 May 1985
- Employees
- 235
- Website
- anikatherapeutics.com ↗
- Head office
- 32 WIGGINS AVENUE, BEDFORD, MA, 01730
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. John HennemanIndependent Chairman of the Board$252,642
- Dr. Cheryl BlanchardPresident, Chief Executive Officer, Director, since 2018$5.1m
- Mr. Stephen GriffinChief Financial Officer, Chief Operating Officer, Executive Vice President$2.6m
- Mr. David ColleranExecutive Vice President, General Counsel, Secretary$1.7m
- Mr. Ian McleodChief Accounting Officer, Vice President, Treasurer
- Mr. Joseph CapperIndependent Director$196,987
- Ms. Sheryl ConleyIndependent Director$221,629
- Mr. Gary FischettiIndependent Director$215,238
- Mr. William JellisonIndependent Director$198,368
- Dr. Glenn LarsenIndependent Director$212,488
- Mr. Stephen RichardIndependent Director$227,625
- Ms. Susan VogtIndependent Director$223,988
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 28
- Social
- 56
- Governance
- 39
- Direct emissions (scope 1)
- 1,559 t
- Energy emissions (scope 2)
- 2,085 t
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Anika Therapeutics Inc is a renowned and established biotechnology company that possesses several strengths in the market. These include:
Weaknesses
- Despite its strengths, Anika Therapeutics Inc also faces certain weaknesses that can hinder its growth and competitiveness. Some of these weaknesses include:
Opportunities
- Anika Therapeutics Inc can capitalize on various opportunities in the biotechnology industry to drive growth and expand its market share. These opportunities include:
Threats
- Anika Therapeutics Inc must also be mindful of potential threats in the market that can impact its operations and profitability. Some of these threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.